3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Motor Activity
12
Breast Neoplasms
9
Neoplasms
6
Leukemia, Myeloid, Acute
3
Prostatic Neoplasms
2
Patient Compliance
2
Neoplasm Metastasis
2
Fatigue
2
Depression
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Weight Loss
1
Weight Gain
1
Smoking Cessation
1
Peripheral Nervous System Diseases
1
Overweight
1
Ovarian Neoplasms
1
Obesity
1
Neuroectodermal Tumors, Primitive
1
Medulloblastoma
1
Lung Neoplasms
1
Insulin Resistance
1
Infratentorial Neoplasms
1
Fallopian Tube Neoplasms
1
Disease
1
Cognitive Dysfunction
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Bone Metabolism Biomarkers
1
Body Weight Changes
1
Interventions
Gemcitabine
58
Cisplatin
32
Oxaliplatin
28
Fluorouracil
21
lenvatinib
19
durvalumab
18
Capecitabine
17
Leucovorin
15
pembrolizumab
10
tislelizumab
9
apatinib
9
Floxuridine
8
Specimen Handling
7
Panitumumab
7
Magnetic Resonance Spectroscopy
7
Albumin-Bound Paclitaxel
7
sintilimab
6
pemigatinib
6
Radiotherapy
6
Irinotecan
6
Drug Therapy
6
Biopsy
6
tremelimumab
5
olaparib
5
camrelizumab
5
Taxes
5
S 1 (combination)
5
Nivolumab
5
Folfox protocol
5
Bevacizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Cholangiocarcinoma
×
Exercise
×
Clear all
NCT02162914
2020-07-31
REACHIN
Erasme University Hospital
Phase 2
Unknown
66 enrolled